XenaCare Holdings Inc. (OTCBB: XCHO) announced today, after an 8-month development program, the official launch of their new product called the SunPill(R).
Johnson & Johnson will provide a pre-recorded webcast for financial analysts on Friday, May 9 at 4:00 p.m. (Eastern Time) to coincide with the American Pain Society's (APS) annual meeting in Tampa, Fla. Phase 3 clinical data presentations on investigational tapentadol immediate release (IR), a novel centrally acting oral analgesic, will be presented for the first time at APS.
A new imaging device, ei-Nav/Artemis(TM), now officially cleared by the U.S. Food and Drug Administration (FDA), offers urologists breakthrough technology that will significantly help in the fight against prostate cancer. Artemis, designed by Eigen, a Northern California-based company known for developing innovative, affordable medical imaging solutions, will be introduced at the American Urological Association's (AUA) annual meeting May 17 - 22 in Orlando, FL.
RTI Biologics Inc. (RTI) (NASDAQ: RTIX), a leading processor of orthopedic and other biologic implants, announced today that the company's revenues were $29.9 million for the first quarter of 2008, compared to $22.0 million for the first quarter 2007.
NeoGenomics, Inc. (OTC Bulletin Board: NGNM) announced today that it plans to release its first quarter 2008 financial results on Wednesday, May 7, 2008.
Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) today announced its 2008 first quarter earnings release date. Separately, Noven also announced an upcoming investor presentation.
BioDelivery Sciences International, Inc. (Nasdaq: BDSI) today announced that four scientific posters for its lead product, BEMA(TM) Fentanyl, currently under review by the U.S. Food and Drug Administration (FDA) as a potential treatment for breakthrough pain (BTP) in opioid-tolerant patients with cancer, will be presented at the 27th Annual Scientific Meeting of the American Pain Society (APS), May 8-10, in Tampa, Florida. The scientific presentations will highlight the Phase III efficacy and safety data as well as the pharmacokinetics of BEMA(TM) Fentanyl. The posters will be presented on May 8 and 9.
GBI is one of the earliest biopharmaceutical contract manufacturing organizations (CMOs), established in 1992. GBI specializes in process development and cGMP compliant mammalian cell culture manufacturing of bio-therapeutics for pre-clinical studies through Phase III clinical trials. The company and its predecessor, The Goodwin Institute for Cancer Research, have been operating in the biologics CMO sector since the early 1980's. GBI's clients include small to midsized biotech companies throughout North America and Europe, universities, renowned cancer research institutes and various branches of the U.S. government. GBI was acquired in 2004 by Wallace Pharmaceuticals Pvt. Ltd., a multi-specialty pharmaceutical manufacturer and distributor based in Goa, India. GBI and Wallace together offer clients the experience of an established US Contract Manufacturing Organization together with the potential for timeline and cost-effective scale up manufacturing in India.
Solei Systems, Inc. (Pink Sheets: SOLI) (the "Company") announced today that their stock is now up and trading on the Pink Sheets. The stock is now quoted under ticker symbol "SOLI". Filings are complete at PinkSheets.com. From this point Solei will continue on toward becoming a fully reporting Company and a senior exchange listing.
MiMedx Group, Inc. (OTC Bulletin Board: MDXG) announced today that Ronald G. Wallace, former President of UPS International, has been appointed to its Board of Directors, effective April 29, 2008.
Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) today announced that its Vice President of Marketing & Sales, W. Neil Jones, has indicated that he plans to leave the company in order to pursue other interests. Jones will remain with Noven for a transition period through the end of May 2008. Noven is working with a national executive recruiting firm to identify Jones's successor.
Jupiter Medical Center (JMC) and the University of Miami (UM) Miller School of Medicine today announced an affiliation agreement that brings northern Palm Beach County access to an academic medical center with the resources and levels of specialty care traditionally available only at a major university teaching hospital.
A change in Chinese meat consumption habits since 1995 is diverting eight billion bushels of grain per year to livestock feed and could empty global grain stocks by September 2010, according to a new study from Biofuels Digest.
Millennium Biotechnologies Inc., wholly-owned subsidiary of Millennium Biotechnologies Group, Inc. (OTC Bulletin Board: MBTG), announced today that SURGEX(TM) has become the official sports nutrition drink of The Edge Training Facility, www.edgebasketball.com, Florida's premier basketball training facility for NBA stars and young emerging basketball talent. Dee Brown, former Boston Celtic, Orlando Magic Toronto Raptor player, winner of the "no look" 1991 Slum Dunk Contest and WNBA Head Coach, is the CEO and head instructor at The Edge Training Facility. At the Edge Training Facility he and his experienced instructors work with current NBA stars and young basketball players to improve their strength and basketball skills.
Cross Country Healthcare, Inc. (Nasdaq:CCRN) announced today that it is scheduled to make a presentation on Wednesday, May 14, 2008, at 5:20 p.m. Pacific Time at the Banc of America Securities Health Care Conference being held at the Four Seasons Hotel in Las Vegas, Nevada.
Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) announced today that continued analysis of the unblinded full data set on its pivotal Fast-Tracked Phase 3 Trial of SinuNase(TM) (topical amphotericin B 0.01% suspension) for chronic sinusitis has demonstrated that among patients with objective evidence of more intense inflammation in chronic sinusitis at the time of enrollment, the efficacy of SinuNase compared to control lavage in reducing inflammation is statistically significant. In particular, among those patients who started the trial with more severe nasal inflammation causing greater polyposis and more severe sinus inflammation causing greater mucosal thickening on CT scan at enrollment, patients in the SinuNase arm of the study achieved a statistically significant reduction in fungal-induced inflammation as judged by a reduction in eMBP in the mucus and nasal polyposis reduction (p-value = 0.03). The eMBP is a test for an inflammatory cytokine found in the nasal mucus and which is specific for fungal-induced inflammation, and polyposis is an inflammatory manifestation that is specific for chronic sinusitis. The unblinded data set has shown, also, that patients with more intense inflammation and symptom severity at baseline were more likely to benefit from SinuNase with a statistically significant reduction in a patient reported outcome (PRO) for chronic sinusitis compared to the control lavage.
Siemens Communications, Inc. has announced the 2007 reseller partner sales achievement awards. The winners, members of the Siemens Enterprise Partner Program, were honored at the 2008 Siemens Enterprise Partner Forum held in March in Orlando, FL.
Exactech, Inc. (Nasdaq:EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today revenue of $39.8 million for the first quarter of 2008, an increase of 34% compared to $29.6 million for the first quarter of 2007. Net income for the quarter was $2.8 million, or $0.23 per diluted share, a gain of 49% from the $1.9 million, or $0.16 per diluted share, in the same quarter a year ago. First quarter diluted earnings per share included a gain of $0.03 due to a forward currency call option and a loss of $0.01 per share due to Exactech's minority investment in Altiva prior to the acquisition.
Affymetrix, Inc. (Nasdaq:AFFX) today announced that company management will provide a corporate overview at four upcoming financial conferences in May.
Goodwin Biotechnology, Inc. (GBI) announced last week the completion of construction of their expanded manufacturing suites. This expansion included the doubling of the cGMP manufacturing space and the addition of a 200L and 500L stirred tank bioreactor train to their hollow fiber and perfusion capabilities. On April 23rd the GBI team, together with representatives of GBI's parent company, Wallace Pharmaceuticals and key invited guests celebrated the commissioning of their new facility with a ribbon cutting ceremony and champagne toast.
Previous
